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Abstract
Background: Viral hepatitis is a serious global public health problem affecting billions of people globally, and both
hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are rapidly spreading in the developing countries
including Bangladesh due to the lack of health education, poverty, illiteracy and lack of hepatitis B vaccination.
Also there is lack of information on their prevalence among the general population. So, a population-based
serological survey was conducted in Dhaka to determine the prevalence and risk factors of HBV and HCV
infections.
Methods: Healthy individuals were selected for demographic and behavioural characteristics by stratified cluster
sampling and blood tested for hepatitis B surface antigen (HBsAg), antibody to HBV core antigen (anti-HBc), and
anti-HCV antibodies (anti-HCV).
Results: From June 2005-November 2006, 1997 participants were screened for HBsAg, anti-HBc and anti-HCV, 738
(37%) were males with mean (SD) age of 24 (14) years. HBV-seropositivity was documented in 582 (29%)
participants: 14 (0.7%) were positive for HBsAg, 452 (22.6%) for anti-HBc and 116 (5.8%) for both HBsAg and anti-
HBc. Four (0.2%) participants were positive for anti-HCV, and another five (0.3%) for both anti-HBc and anti-HCV.
Ninety-six/246 (39%) family members residing at same households with HBsAg positive participants were also HBV-
seropositive [74 (30.1%) for anti-HBc and 22 (8.9%) for both HBsAg and anti-HBc], which was significantly higher
among family members (39%) than that of study participants (29%) (OR 1.56; p < 0.001). In bivariate analysis, HBV-
seropositivity was significantly associated with married status (OR 2.27; p < 0.001), history of jaundice (OR 1.35; p =
0.009), surgical operations (OR 1.26; p = 0.04), needle-stick injuries (OR 2.09; p = 0.002), visiting unregistered health-
care providers (OR 1.40; p = 0.008), receiving treatment for sexually transmitted diseases (STD) (OR 1.79; p = 0.001),
animal bites (OR 1.73; p < 0.001); ear-nose-body piercing in females (OR 4.97; p < 0.001); circumcision (OR 3.21; p <
0.001), and visiting community barber for shaving in males (OR 3.77; p < 0.001). In logistic regression analysis,
married status (OR 1.32; p = 0.04), surgical operations (OR 1.39; p = 0.02), animal bites (OR 1.43; p = 0.02), visiting
unregistered health-care providers (OR 1.40; p = 0.01); and ear-nose-body piercing in females (OR 4.97; p < 0.001)
were significantly associated with HBV-seropositivity.
Conclusions: The results indicate intermediate level of endemicity of HBV infection in Dhaka community, with
much higher prevalence among family members of HBsAg positive individuals but low prevalence of HCV
infections, clearly indicating need for universal hepatitis B vaccination. The use of disposable needles for ear-nose-
body piercing need to be promoted through public awareness programmes as a preventive strategy.
* Correspondence: ashrafh@icddrb.org
1ICDDR,B (International Centre for Diarrhoeal Disease Research, Bangladesh),
68 Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka 1212, Bangladesh
Ashraf et al. BMC Infectious Diseases 2010, 10:208
http://www.biomedcentral.com/1471-2334/10/208
© 2010 Ashraf et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Viral hepatitis is a serious public health problem affect-
ing billions of people globally. Caused mainly by hepati-
tis viruses A, B, C, D and E, and rarely by
cytomegalovirus (CMV), Epstein-Barr virus (EBV) and
fungal infections, the spectrum of hepatitis range from
sub-clinical to milder and life threatening illness includ-
ing hepatocellular carcinoma [1,2]. Globally two billion
people are infected with HBV, and 350 millions of them
have chronic (lifelong) infections, who are at high risk
of death from liver cirrhosis and liver cancer that kill
more than one million people globally each year [3]. In
the Middle East and Indian sub-continent, HBV infec-
tion is of intermediate endemicity with chronic HBV
carriage rate of 2-5% among general population [3]. In
Bangladesh, there is paucity of information on the pre-
valence of HBV infections among general population
and majority of the previous studies were conducted in
selected group of people with higher risk factors such as
blood donors, drug addicts, commercial sex workers
(CSWs) or hospitalised patients [4-8]. However, a recent
report showed 5.5% HBsAg positivity among the general
population living in Savar, a semi-urban area on the
outskirts of Dhaka [9]. Although HBsAg is the most reli-
able biological biomarker of HBV infection, and the
anti-HBc antibody is an important marker for surveying
the burden of HBV infection as it persists even after
resolution of infection, and thus identifies both past and
current HBV infection [10]. As majority of the previous
studies in Bangladesh examined only the prevalence of
HBsAg [2,4-7,11-16] and most of them were conducted
in selected group of people with higher risk factors, we
decided to estimate the prevalence of both HBsAg and
anti-HBc among the general population of Dhaka,
Bangladesh.
HCV infections is also a major global health problem
with an estimated 170 million people chronically
infected and 3-4 million people get new infections each
year [17]. HCV infections lead to acute hepatitis in 20%
cases, and chronic hepatitis in 50-80% cases, of whom
10-20% develop liver cirrhosis [17-20] and 1-5% develop
liver cancer in 20-30 years [17]. The prevalence of HCV
infection varies throughout the world with significant
regional and ethnic differences. The highest number
reported from Egypt following parenteral antischisto-
somal therapy with a prevalence of anti-HCV of 6-28%
(mean 22%) depending on the regions [21]. Although
some risk factors for acquiring HCV infections are pre-
sent in 50% cases, no recognizable transmission factor
could be identified in the remaining 50% [17,22]. As
there is also lack of information on the prevalence of
HCV infection among the general population and nearly
all previous studies were conducted in selected group of
people [8,23-25], we also decided to estimate the preva-
lence of anti-HCV in the same population.
It is evident that HBV and HCV infections are both
major global health problems, and they are rapidly
spreading in developing countries due to the lack of
health education, poverty, illiteracy and lack of hepatitis
B vaccination. As many chronically infected individuals
remain asymptomatic, and thus undetected for many
years, we planned this population-based serological
s t u d yt od e t e r m i n et h ep r e v a l e n c eo fH B s A g ,a n t i - H B c ,
and anti-HCV among all age groups and to identify the
possible risk factors for acquiring the infections. We
hoped that the findings might guide eventually the
development, adaptation, and evaluation of prevention
strategies.
Methods
Study site
The study was conducted in Kamalapur, a densely popu-
lated community in urban Dhaka, the capital city of
Bangladesh. The International Centre for Diarrhoeal
Disease Research, Bangladesh (ICDDR, B) has been
using this as its first urban field site since 1998. It is an
impoverished area comprised of seven communities in
four municipal wards with 200,000 residents in an area
of 4 km
2 (29,663 persons/km
2), 11.2% of whom are
under-5 children, with a mean (range) house hold size
o f4( 1t o2 0 )p e r s o n s .T h e yh a v eam e d i a nm o n t h l y
household income of US $50. Kamalapur is divided into
seven geographical strata and 450 clusters, each with
approximately 100 households. The community had all
the potential reported risk factors, such as overcrowd-
ing, low income, poor sanitation for high disease burden
of infectious diseases such as diarrhea, and pneumonia
[26,27] and hepatitis.
Sample size
Assuming that 6% of the population will have a HBsAg
positive status with 1% precision and 95% confidence
l i m i t ,w ee s t i m a t e dt h es a m p l es i z et ob e1 9 5 5 .F o r
HCV, we assumed that 5% of the population will have
an anti-HCV positive status with 1% precision and 95%
confidence limit, we estimated the sample size to be
1825. Assuming a refusal rate of 10%, we determined
t h es a m p l es i z et ob e2 0 0 0 .T og e ts u f f i c i e n tn u m b e ro f
people to detect the above mentioned prevalence, we
considered Kamalapur, Dhaka, as the population suitable
for this study.
Randomization
A population based, cross-sectional survey was con-
ducted in 2000 individuals, aged 0-60 years during 2005-
2006. For achieving this sample, all the 450 geographical
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pling. The first household of the cluster was chosen ran-
domly and if a locked house was encountered, then the
next household in same direction replaced that.
Study procedure
The trained field research assistants (FRAs) visited the
selected households in accordance with the randomisa-
tion list and approached the head of the family. They
explained the purpose and objective of the study and
obtained written informed consent from study partici-
pants, or parents for eligible children. They administered
a pre-tested questionnaire to the participants at a
mutually agreed date at the clinic, when a research physi-
cian collected 4 ml of blood from the antecubital veins
under aseptic conditions. The blood specimens were cen-
trifuged at the clinic within 6 hours and separated sera
were transported to the Dhaka Hospital of ICDDR, B,
a n ds t o r e da t- 2 0 ° Ci na l i q u o t s .F o rd i a g n o s i so fH B V
infection, HBsAg and anti-HBc were determined using
commercially available enzyme-linked immunosorbent
assay (ELISA) kits (Manufacturer: DiaSorin S. A., Italy).
For diagnosis of HCV infection, anti-HCV antibody was
detected using a third-generation ELISA kit (Manufac-
turer: DiaSorin S. A., Italy). After collection of blood
samples, the research physician interviewed the partici-
pants (parents if the participant was a minor) in a private
set up within the clinic to collect their socio-demo-
graphic characteristics including age, gender, years of
education, socio-economic status, occupation, income,
and marital status by using a structured questionnaire.
They were also asked about the type of health care provi-
ders they consulted for health problems, history of jaun-
dice, history of taking injections, previous surgical
procedures, frequency of dental visits, receiving blood or
blood products, history of current/past use of intravenous
drugs, siblings, history of tattooing; ear-nose-body pier-
cing in females, and circumcision and visiting community
barbers for shaving in males. Some questions about sex-
ual behaviour such as having multiple sexual partners,
having received treatment for STD were asked to partici-
p a n t s1 8y e a r so fa g eo ro l d e rb yr e s e a r c hp h y s i c i a no f
t h es a m es e x .T h es t u d yw a sapproved by the Research
and Ethical Review Committees of ICDDR, B.
The laboratory test results were kept confidential and
the research physician shared the results with the parti-
cipants. Infected individuals were provided with appro-
priate information on the prevention of spread of these
infections to others, and referred them to the nearest
public health care facilities.
Serological tests
We only performed HBsAg, anti-HBc, and anti-HCV to
reduce the laboratory test costs.
HBsAg
is the serologic hallmark of HBV infection. It appears in
serum 1-10 weeks after an acute exposure to HBV, prior
to the onset of hepatitic symptoms. The sensitivity of
HBsAg is 100%, the specificity is 99.7%, and the limit of
detection is 0.05 PEI units/ml. The lower limit of detec-
tion, PEI unit was explained as the analytical sensitivity
that may be expressed as the limit of detection, which is
the minimal amount of specific analyte precisely detect-
able by the assay. A conversion of 0.05 PEI units/ml to
international unit (IU) values was evaluated by testing
HBsAg international reference material from World
Health Organization NIBSC 1
st International Standard,
code 80/549; (HBsAg, subtype ad) and limit of detection
was found to be 0.05 IU/ml. When the same protocol
was used with Paul-Ehrlich-Institute (Germany), HBsAg
reference preparation (subtypes ad, ay), the detection
limit came to 0.03 PEI units/ml. If the infection is self-
limited, HBsAg disappears in most patients before the
serum hepatitis B surface antibody (anti-HBs) can be
detected. Persistence of HBsAg for more than six
months implies chronic infection.
Anti-HBc
identifies individuals with both current and past HBV
infection (prevalence). The sensitivity of anti-HBc is
100%, the specificity is 99.83%, and the limit of detec-
tion is < 0.5 PEI units/ml. Almost all HBV-infected peo-
ple usually develop anti-HBc. Detection of anti-HBc
indicates exposure to HBV, which may be acute,
chronic, or resolved infection. Fourteen (0.7%) study
subjects were expressing HBsAg positive, but negative
for anti-HBc. Although rare, this serological profile of
HBsAg positive, but anti-HBc negative is not that excep-
tional. In addition to the diagnostic kits efficacy, the
immunosuppressive state of the subject may also contri-
bute to such profile [28].
Anti-HCV
The discovery of HCV in 1989 led to the development
of an antibody diagnostic assay (anti-HCV) based on
viral recombinant peptides. The third generation assays
(ELISA-3) have been introduced incorporating antigens
from putative neucleocapsid, NS3, NS4, and NS5
regions, and become positive in 2-3 weeks after the
infection [29]. They are currently the most widely used
screening tests for HCV and are more sensitive and spe-
cific than earlier generation tests in screening blood
donors [30]. Detection of anti-HCV indicates present or
previous HCV infection but cannot discriminate acute
from chronic or resolved HCV infection [31].
Statistical Analysis
All data were analysed using Statistical Package for
Social Sciences (SPSS) version 10.0 [32]. The analysis
was carried out at three levels of descriptive, bivariate
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socio-demographic variables and other characteristics of
the sampled population were computed. Means and SD
were calculated for quantitative variables and propor-
tions for categorical variables. Percentage with 95% con-
fidence interval (CI) was used to describe the
prevalence. OR and 95% CI was calculated for each
association. Associations among independent variables
were assessed using appropriate tests, such as x
2 or
Fisher’s exact tests, when indicated before performing
logistic regression analysis. Multiple logistic regression
models were used to examine the association between
independent variables and the main outcome variable,
HBV-seropositivity, while controlling for the effects of
other covariates. All variables which were associated
with outcome in bivariate analysis were included in the
model. In logistic model, reference category (OR = 1)
for OR estimate was HBV-negative participants. A prob-
ability of < 0.05 was considered as statistical significant.
The final logistic regression model was obtained by for-
ward selection based on single variables and their possi-
ble interactions. Given small number of hepatitis C
infections, no tests of association could be performed.
Results
From June 2005 to November 2006, 2004 subjects were
initially selected for the study, of whom 1997 participants
were enrolled into the study, mostly young adults, 738
(37%) were males and 1259 (63%) were females, with a
mean (SD) age of 24 (14) years. Seven subjects were not
enrolled as we failed to confirm the serological diagnosis.
The evidence for current or previous HBV infection was
documented in 582 (29%) participants with a male to
female ratio of 40:60 and a mean (SD) age of 28 (13)
years. HBsAg was positive in 14 (0.7%) participants, anti-
HBc was positive in 452 (22.6%) participants, and both
HBsAg and anti-HBc were positive in 116 (5.8%) partici-
pants (Table 1). Four (0.2%) participants were positive for
anti-HCV, and another five (0.3%) for both anti-HBc and
anti-HCV (Table 1). The HBV positivity was significantly
more among females than male participants (40% vs.
10%) (OR 5.75; p < 0.001). The HBV positivity among
under-5 children were 60/208 (28.8%): HBsAg was
positive in 5/208 (2.4%) children, anti-HBc was positive
in 34/208 (16.3%), and both HBsAg and anti-HBc were
positive in 21/208 (10%) children (Table 1). The anti-
HBc positivity was significantly less among under-5 chil-
dren than that of study participants (16.3% vs. 22.6%)
(OR 1.47; p < 0.01). After receiving laboratory results,
246 family members residing at the same household as
that of the study participants’ positive for HBsAg were
similarly studied. In total, 96/246 (39%) of them were
HBV-seropositive with a male to female ratio of 45:55
and a mean (SD) age of 21 (16) years: 74 (30.1%) were
positive for anti-HBc, and 22 (8.9%) were positive for
both HBsAg and anti-HBc (Figure 1). In fact, the preva-
lence of HBV infection among the family members (96/
246; 39%) was significantly higher than that of the study
participants (582/1997; 29%) (OR 1.56; p < 0.001). Hepa-
titis B vaccination was found to be protective against
HBV infection [only 10/582 (1.7%) of the HBV positive
participants were vaccinated in contrast to 66/1406
(4.7%) of the HBV negative participants were vaccinated]
(OR 2.82; p = 0.001).
Risk factors for HBV-seropositivity
In bivariate analysis, HBV-seropositivity (including
HBsAg positive, or anti-HBc positive, or both HBsAg
a n da n t i - H B cp o s i t i v ep a r t i cipants) was significantly
associated with a variety of sociodemographic and beha-
vioral independent variables, such as married status (OR
2.27; p < 0.001), history of jaundice (OR 1.35; p =
0.009), surgical operations (OR 1.26; p = 0.04), needle-
stick injuries (OR 2.09; p = 0.002), visiting unregistered
health-care providers (OR 1.40; p = 0.008), receiving
treatment for STD (OR 1.79; p = 0.001), animal bites
(OR 1.73; p < 0.001); ear-nose-body piercing in females
(OR 4.97; p < 0.001); circumcision (OR 3.21; p < 0.001)
and visiting community barber for shaving in males (OR
3.77; p < 0.001) (Table 2).
After adjusting for potential confounding effects in
the logistic regression analysis, married status (OR 1.32;
p = 0.04), surgical operations (OR 1.39; p = 0.02), ani-
mal bites (OR 1.43; p = 0.02), visiting unregistered health-
care providers (OR 1.40; p = 0.01); and ear-nose-body
piercing in females (OR 4.97; p < 0.001) remained
Table 1 Groups of study participants and family members based on the serological test results
Positive test results Study participants
(n = 1997)
Under-5 children
(n = 208)
Family members
(n = 246)
Interpretation
1. HBsAg 14 (0.7%) 5 (2.4%) 0 Acute or chronic HBV infection
2. Anti-HBc 452 (22.6%) 34 (16.3%) 74 (30%) Exposure to HBV, which may be acute, chronic or
resolved infection
3. Both HBsAg and anti-HBc 116 (5.8%) 21 (10%) 22 (8.9%) Acute or chronic HBV infection
4. Anti-HCV 4 (0.2%) 0 0 Present or previous HCV infection
5. Both anti-HBc and anti-HCV 5 (0.3%) 0 1 (0.4%) Mixed HBV and HCV infections
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In the above regression model, both age and sex were
retained as covariates to control their influence on other
covariates.
Discussion
Although prevalence studies are not always easily under-
taken in the developing countries such as Bangladesh
due to high cost, we made efforts to prospectively esti-
mate the prevalence of HBV and HCV infections among
a population living at Kamalapur, a densely populated
community in Dhaka, the capital city of Bangladesh.
The results of our study suggest a high HBV exposure
among our study population. The HBsAg prevalence of
6.5% among our study population is within the range of
2-7%, reported by previous studies from selective popu-
lation of Dhaka: 3% among healthy adults and children
[33] and 3.5% among pregnant women [5]; however,
much lower rate (0.8%) was observed among school
children [16]. The prevalence was also within the same
range as reported from some high-risk groups from
Dhaka: 4.4% among non-injectable drug users (non-
IDUs) and 6.2% in injectable drug users (IDUs) [24];
and 5.9% among truck drivers and helpers [34]. The
higher rates among our study population could be
attributed to the general lack of proper health care
because of deprived socio-economic status (monthly
household income of US $50) and less public health
awareness about the transmission of HBV infection as
well as the lack of hepatitis B vaccination in the com-
munity. Our prevalence was similar (6.5% vs. 6.4%) to
that reported from the Rangpur district of Bangladesh
[13]. However, higher prevalence has also been reported
among the high-risk groups of Dhaka: 7.6% among
women at a STD clinic [23]; 8% among IDUs [6]; 8.6%
among surgically operated patients [7]; 9.7% among
CSWs [8]; 19% among hepatitis patients [2]; and 47%
among hepatocellular carcinoma patients [14].
(Note:  *HBV-seropositivity includes HBsAg positive/anti-HBc positive/both HBsAg and anti-
HBc positive study participants)  
1997 persons
Both HBV and HCV 
negative: 1406 (70.4%) 
Both anti-HBc and anti-
HCV positive: 5 (0.3%) 
Anti-HCV positive: 
4 (0.2%) 
*HBV positive: 
582 (29%) 
Both HBsAg and anti-
HBc positive: 116 (5.8%) 
Anti-HBc positive: 
452 (22.6%) 
HBsAg positive: 
14 (0.7%) 
246 family members of 
HBsAg positive subjects 
Both anti-HBc and anti-HCV positive: 
1 (0.4%) 
*HBV positive: 
96 (39%) 
Both HBsAg and anti-HBc positive: 
22 (8.9%) 
Anti-HBc positive: 
74 (30%) 
Figure 1 Study Profile
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Risk factors *HBV positive n = 582 (100%) HBV negative n = 1406 (100%) Odds Ratio (95% CI) p-value
1. Marital status
Un-married 200 (34.4) 764 (54.3) 1.0
Married 382 (65.6) 642 (45.7) 2.27 (1.85-2.79) < 0.001
2. History of jaundice
No 431 (74.1) 1116 (79.4) 1.0
Yes 151 (25.9) 290 (20.6) 1.35 (1.07-1.70) 0.009
3. Previous surgery
No 431 (74.1) 1101 (78.3) 1.0
Yes 151 (25.9) 305 (21.7) 1.26 (1.00-1.59) 0.04
4. Circumcision in males only (n = 734)
No 37 (15.9) 190 (37.8) 1.0
Yes 195 (84.1) 312 (62.2) 3.21 (2.13-4.86) < 0.001
5. Needle-stick injuries
No 550 (94.5) 1368 (97.3) 1.0
Yes 32 (5.5) 38 (2.7) 2.09 (1.26-3.47) 0.002
6. Ear-nose-body piercing in females only (n = 1254)
No 14 (4) 155 (17.1) 1.0
Yes 336 (96) 749 (82.9) 4.97 (2.76-9.10) < 0.001
7. Animal bites
No 451 (77.5) 1204 (85.6) 1.0
Yes 131 (22.5) 202 (14.4) 1.73 (1.34-2.23) < 0.001
8. Visiting community barber for shaving in males only (n = 734)
No 64 (27.6) 296 (59) 1.0
Yes 168 (72.4) 206 (14) 3.77 (2.65-5.37) < 0.001
9. Visiting unregistered health care providers
No 98 (16.8) 310 (22.0) 1.0
Yes 484 (83.2) 1096 (78.0) 1.40 (1.08-1.81) 0.008
10. Receiving treatment for STD
No 528 (90.7) 1330 (94.6) 1.0
Yes 54 (9.3) 76 (5.4) 1.79 (1.23-2.61) 0.001
(Note: *HBV-seropositivity includes HBsAg positive/anti-HBc positive/both HBsAg and anti-HBc positive study participants)
Table 3 Multiple logistic regression analysis for being *HBV-seropositive
Risk factors *HBV positive n = 582 (100%) HBV negative n = 1406 (100%) Adjusted Odds Ratio
(95% CI)
p-value
1. Married status 382 (65.6) 642 (45.7) 1.32 (1.00-1.73) 0.046
2. Previous surgery 151 (25.9) 305 (21.7) 1.39 (1.05-1.82) 0.02
3. Ear-nose-body piercing in females
(n = 1254)
336/1085 (31) 14/169 (8.3) 4.97 (2.76-9.10) < 0.001
4. Animal bites 131 (22.5) 202 (14.4) 1.43 (1.04-1.96) 0.024
5. Visiting unregistered health-care providers 484 (83.2) 1096 (78.0) 1.40 (1.08-1.82) 0.012
(Note: *HBV-seropositivity includes HBsAg positive/anti-HBc positive/both HBsAg and anti-HBc positive study participants.
Initial models included the variables age, sex, married status, history of jaundice, surgical operation, circumcision, needle-stick injuries, animal bites, visiting
unregistered health care providers, receiving treatment for STD, ear-nose-body piercing in females, circumcision, and visiting community barber for shaving in
males. Significant factors were retained in the final model)
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was similar (22.6% vs. 21.1%) to that reported from
healthy adults and children [33] but lower than that
reported from the high-risk groups of Dhaka: 24.1% in
non-IDUs and 31.8% in IDUs [24]; 35.2% among women
at a STD clinic [23]; 48.1% among truck drivers and
helpers [34]; 49.3% among women living near a truck
stand [25]; and 73% among CSWs [8].
T h e0 . 2 %p r e v a l e n c eo fa n t i - H C Vo b s e r v e di no u r
study population is lower than that reported from high-
risk groups of Dhaka: 0.8% among truck drivers and
helpers [34]; 0.9% among women at a STD clinic [23];
1.6% among women living near a truck stand [25]; 5.8%
in non-IDUs and 24.8% in IDUs [24]; and 13% among
hepatitis patients [2].
The intermediate rate of chronic HBV carriage of
around 3% was observed in most general populations
(clinics, villagers), suggesting that this population would
benefit from universal hepatitis B vaccination [11]. In
2004, the Government of Bangladesh and UNICEF have
introduced the hepatitis B vaccine into the Expanded
Programme on Immunization (EPI) against six infectious
diseases. The successful continuation of the programme
is expected to reduce chronic HBV infections in the next
generations. Since 90% of the HBV infected older chil-
dren and adults successfully clear the infection and do
not become chronic carriers, the prevalence of HBsAg
alone might not describe the total burden of HBV infec-
tions. Therefore, estimation of the prevalence of anti-
HBc, in addition to the estimation of the prevalence of
HBsAg which is the most reliable biological biomarker of
HBV infection, is much more informative about indicator
of HBV disease burden among the population. This prob-
ably accounts for our higher anti-HBc (22.6%) than
HBsAg (6.5%) seropositivity rates (Figure 1).
There are some limitations of our study. First, we did
not perform some diagnostic tests for HBV, e.g. anti-HBc
IgM, the presence of which indicates acute infection; and
anti-HBs that differentiates susceptible persons from those
immune persons, which can be due either to natural infec-
tion or hepatitis B vaccination. Second, we did not per-
form some diagnostic tests for HCV, e. g. recombinant
immunoblot assay (RIBA) to confirm HCV exposure, or
polymerase chain reaction (PCR) to detect HCV infected
individuals. All the above limitations are mainly due to
study cost constraints, mostly related to laboratory tests.
The third limitation is that the study was conducted in a
single population in Dhaka, and may not reflect all of Ban-
gladesh, although the literature we have cited suggests that
it should. The fourth limitation is the selection of Kamala-
pur as the study site, as the activities of ICDDR,B might
influence the prevalence of HBV and HCV, which might
be a biased location because the people of this area might
have altered KAP (knowledge, attitude and performance)
regarding infectious diseases due to prolonged presence of
ICDDR,B team and their health education. A final limita-
tion is the relatively short observation window, which may
have missed important secular trends in the background
prevalence of both the hepatitis B and C viruses.
Conclusions
The results of our study indicate intermediate level of
endemicity of HBV infection such as overall intermediate
prevalence of HBsAg; but high anti-HBc, indicating that
the members of this urban community are highly exposed
to a high prevalence of the hepatitis B virus, which may be
acute, chronic or resolved, in an urban community in
Dhaka, Bangladesh. We also noted higher prevalence
among the family members residing at the same house-
hold of that of the HBsAg positive individuals, suggesting
likely intra-household transmission. However, we observed
a much lower prevalence of HCV infections in the same
community. We also identified some independent risk fac-
tors, which could help health care providers and policy
makers in designing and initiating effective preventive pro-
grammes. The findings also highlight the need for preven-
tion and control of HBV infection in Bangladesh by
implementing universal hepatitis B vaccination and creat-
ing public awareness to promote the use of disposable
needles for ear-nose-body piercing.
Future follow-up studies are required to confirm the
family clustering effect of HBV infection as observed in
Korea [35], and to better define the transmission
dynamics, and to identify their common risk factors for
acquiring HBV infection by comparing family members
of HBsAg positive participants with those who are nega-
tive for the tests. Such a study is planned to be con-
ducted for the same community in Dhaka. Further,
more long-term population-based surveillance studies,
with extended serology of HBV infection, are needed to
more accurately assess the hepatitis B true disease bur-
den in Bangladesh, the impact of vaccination, and to
guide prioritization of scarce health care resources.
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